Genomics

Dataset Information

0

Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy [RNA-Seq]


ABSTRACT: Deep sequencing has revealed that epigenetic modifiers are the most mutated genes in acute myeloid leukemia (AML). Thus, elucidating epigenetic dysregulation in AML is crucial to understand disease mechanisms. Here, we demonstrate that Metal Response Element Binding Transcription Factor 2/Polycomblike 2 (MTF2/PCL2) plays a fundamental role in the Polycomb repressive complex 2 (PRC2) and that its loss elicits an altered epigenetic state underlying refractory AML. Unbiased systems analyses identified the loss of MTF2-PRC2 repression of MDM2 as central to, and therefore a biomarker for, refractory AML. Thus, immature MTF2- deficient CD34+CD38- cells overexpress MDM2, thereby inhibiting p53 that leads to chemoresistance due to defects in cell cycle regulation and apoptosis. Targeting this dysregulated signaling pathway by MTF2 overexpression or MDM2 inhibitors sensitized refractory patient leukemic cells to induction chemotherapeutics and prevented relapse in AML patient-derived xenograft (PDX) mice. Therefore, we have uncovered a direct epigenetic mechanism by which MTF2 functions as a tumor suppressor required for AML chemotherapeutic sensitivity and identified a potential therapeutic strategy to treat refractory AML.

ORGANISM(S): Homo sapiens

PROVIDER: GSE98343 | GEO | 2018/07/31

REPOSITORIES: GEO

Similar Datasets

2018-07-31 | GSE98380 | GEO
2018-07-31 | GSE98378 | GEO
2018-07-26 | GSE72286 | GEO
2018-07-26 | GSE72287 | GEO
2018-05-07 | PXD005821 | Pride
| PRJNA384954 | ENA
2018-04-09 | GSE94300 | GEO
| E-GEOD-16364 | biostudies-arrayexpress
2021-04-21 | GSE167043 | GEO
2021-04-21 | GSE155990 | GEO